GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (NAS:FBLG) » Definitions » Cash Flow from Others

FBLG (FibroBiologics) Cash Flow from Others : $3.53 Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics Cash Flow from Others?

FibroBiologics's cash flow from others for the three months ended in Sep. 2024 was $-2.78 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Sep. 2024 was $3.53 Mil.


FibroBiologics Cash Flow from Others Historical Data

The historical data trend for FibroBiologics's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics Cash Flow from Others Chart

FibroBiologics Annual Data
Trend Dec21 Dec22 Dec23
Cash Flow from Others
- 0.38 7.38

FibroBiologics Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - 7.24 3.10 -4.03 -2.78

FibroBiologics Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.53 Mil.

FibroBiologics Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of FibroBiologics's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroBiologics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.